Zhang Lab

National University of Singapore

Home Research COVID-19 Services Publications People Teaching Job Opening News Forum Lab Only

Online Services

●I-TASSER ●I-TASSER-MTD ●C-I-TASSER ●CR-I-TASSER ●QUARK ●C-QUARK ●LOMETS ●MUSTER ●CEthreader ●SEGMER ●DeepFold ●DeepFoldRNA ●FoldDesign ●COFACTOR ●COACH ●MetaGO ●TripletGO ●IonCom ●FG-MD ●ModRefiner ●REMO ●DEMO ●DEMO-EM ●SPRING ●COTH ●Threpp ●PEPPI ●BSpred ●ANGLOR ●EDock ●BSP-SLIM ●SAXSTER ●FUpred ●ThreaDom ●ThreaDomEx ●EvoDesign ●BindProf ●BindProfX ●SSIPe ●GPCR-I-TASSER ●MAGELLAN ●ResQ ●STRUM ●DAMpred

●TM-score ●TM-align ●US-align ●MM-align ●RNA-align ●NW-align ●LS-align ●EDTSurf ●MVP ●MVP-Fit ●SPICKER ●HAAD ●PSSpred ●3DRobot ●MR-REX ●I-TASSER-MR ●SVMSEQ ●NeBcon ●ResPRE ●TripletRes ●DeepPotential ●WDL-RF ●ATPbind ●DockRMSD ●DeepMSA ●FASPR ●EM-Refiner ●GPU-I-TASSER

●BioLiP ●E. coli ●GLASS ●GPCR-HGmod ●GPCR-RD ●GPCR-EXP ●Tara-3D ●TM-fold ●DECOYS ●POTENTIAL ●RW/RWplus ●EvoEF ●HPSF ●THE-DB ●ADDRESS ●Alpaca-Antibody ●CASP7 ●CASP8 ●CASP9 ●CASP10 ●CASP11 ●CASP12 ●CASP13 ●CASP14

GLASS

You can:

Go to the GPCR, ligand, or experimental data tables.
Go to the experimental data table for text mining information in PubMed ID column.
Go to the GPCR page and check other ligands which interact with it.
Go to the ligand page and check other GPCRs which it interacts with.
Go back to previous page.

GPCR

Name	D(1A) dopamine receptor
Species	Homo sapiens (Human)
Gene	DRD1
Synonym	D1 receptor D1A DADR Gpcr15 dopamine D1 receptor Dopamine-1A receptor [ Show all ]
Disease	Unspecified Hypertension Pain Parkinson's disease Psychiatric disorder Psychotic disorders Schizophrenia Substance dependence Type 2 diabetes Excessive bleeding following childbirth and spontaneous or elective abortion Cocaine addiction Dementia Cognitive disorders [ Show all ]
Length	446
Amino acid sequence	MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTNFFVISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVDRYWAISSPFRYERKMTPKAAFILISVAWTLSVLISFIPVQLSWHKAKPTSPSDGNATSLAETIDNCDSSLSRTYAISSSVISFYIPVAIMIVTYTRIYRIAQKQIRRIAALERAAVHAKNCQTTTGNGKPVECSQPESSFKMSFKRETKVLKTLSVIMGVFVCCWLPFFILNCILPFCGSGETQPFCIDSNTFDVFVWFGWANSSLNPIIYAFNADFRKAFSTLLGCYRLCPATNNAIETVSINNNGAAMFSSHHEPRGSISKECNLVYLIPHAVGSSEDLKKEEAAGIARPLEKLSPALSVILDYDTDVSLEKIQPITQNGQHPT
UniProt	P21728
Protein Data Bank	N/A
GPCR-HGmod model	P21728
3D structure model	This predicted structure model is from GPCR-EXP P21728.
BioLiP	N/A
Therapeutic Target Database	T22118
ChEMBL	CHEMBL2056
IUPHAR	214
DrugBank	BE0000020

Ligand

Name	FENRETINIDE
Molecular formula	C26H33NO2
IUPAC name	(2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
Molecular weight	391.555
Hydrogen bond acceptor	2
Hydrogen bond donor	2
XlogP	7.3
Synonyms	NCGC00090752-05 CAS-65646-68-6 NCGC00261310-01 D04162 Retinamide,N-(4-hydroxyphenyl)- EU-0100625 Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx 15-(4-Hydroxyanilino)retinal # Fenretinide (topical, actinic keratosis and cancer), SciTech Development 33819-EP2295416A2 HMS1361G21 33819-EP2311808A1 IDI1_033889 4-hydroxy(phenyl)retinamide MLS001055399 AB0109574 N-(4-Hydroxyphenyl)-trans-Retinamide AN-7467 RETINOID PROJECT 5 (4-HYDROXYPHENYL)RETINAMIDE (SEERETINOID PROJECT 1, 2, 3, 4) SMR001456303 Tox21_111007_1 BDBM50092055 NCGC00090752-09 CHEBI:42588 NSC374551 dimethyl-9-(2,6,6-trimethylcyclohex- Retinoic acid p-hydroxyphenylamide (2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products 2,6,8-Nonatetraenamide, N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl-, (all-E)- Fenretinidum 33819-EP2298748A2 HMS2089B17 4 HPR LP00625 4HPR MolPort-003-666-842 AK326150 N-(4-hydroxyphenyl)retinamide, 4-HPR SC-76490 SR-01000075917-1 UNII-187EJ7QEXL NCGC00090752-03 BRN 5769490 NCGC00090752-12 CHEMBL7301 Pharmakon1600-01505602 DSSTox_RID_78900 Fenretinide (ILE formulation), Children's Hospital LA (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Fenretinide (soft gel capsule, AMD), ReVision Therapeutics 33819-EP2295055A2 FT-0081247 33819-EP2305642A2 HSCI1_000112 4-HPR McN-R-1967 A835178 N-(4-Hydroxyphenyl)-all-trans Retinamide all-trans-4'-Hydroxyretinanilide RETINOID PROJECT 2 (4-(HYDROXYPHENYL)RETINAMIDE) (SEE RETINOID PROJECT 1,3,4, 5,6) SCHEMBL15703189 SYT-101 NCGC00090752-06 CCG-204713 NSC-374551 D08JAC Retinoic acid p-hydroxyanilide Fenretinida (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide Fenretinide (intravenous, cancer), SciTech Development 15-[(4-hydroxyphenyl)amino]retinal Fenretinide (USAN/INN) 33819-EP2295426A1 HMS1791G21 33819-EP2311829A1 KB-77316 4-Hydroxyphenyl retinamide MLS002701698 AC1NRB1E N-(4-Hydroxyphenyl)all-Trans Retinamide AOB6402 RETINOID PROJECT 6 (4-HPR) (SEE RETINOID PROJECTS 1,2,3,4,5) Spectrum5_001939 Tox21_200989 BML2-E08 NCGC00090752-10 CHEBI:92493 NSC760419 DSSTox_CID_12005 Fenretinide (4-HPR) (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide Fenretinide (oral, AMD), Sytera 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide Fenretinidum [Latin] 33819-EP2298764A1 HMS3261N12 4-(HYDROXYPHENYL)-RETINAMIDE (SEE RETINOID PROJECTS 1 AND 2.) LS-282 646F686 N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraeneamide AKJHMTWEGVYYSE-FXILSDISSA-N NCGC00090752-01 SCHEMBL11703 SR-01000075917-4 W-5119 NCGC00090752-04 BSPBio_001419 NCGC00258542-01 CS-0789 Retinamide, N-(4-hydroxyphenyl)- DTXSID2032005 Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles 1-enyl)nona-2,4,6,8-tetraenamide Fenretinide (soft gel capsule, AMD), Sirion 33819-EP2295406A1 H 7779 33819-EP2311453A1 HY-15373 4-HPR;(4-Hydroxyphenyl)retinamide MFCD00792674 AB00172992-07 N-(4-hydroxyphenyl)-retinamide all-trans-n-(4-hydroxyphenyl)retinamide RETINOID PROJECT 4 (4-HYDROXYPHENYL)RETINAMIDE (SEERETINOID PROJECT 1, 2, AND 3) SMR000677938 Tox21_111007 BCP06908 NCGC00090752-07 CCRIS 3260 NSC-760419 DB05076 Retinoic acid p-hydroxyanilide, >=95% Fenretinida [Spanish] (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7- Fenretinide (iv), Children's Hospital LA 187EJ7QEXL Fenretinide [USAN:INN] 33819-EP2295427A1 HMS1989G21 3670AH Lopac0_000625 4-hydroxyphenylretinamide MLS006010811 AC1Q1QV3 N-(4-Hydroxyphenyl)retinamide RT-101 SR-01000075917 Tox21_500625 BP-13369 NCGC00090752-11 p-Hydroxyphenylretinamide DSSTox_GSID_32005 Fenretinide (Ewing's sarcoma), Cancer Research UK (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University 33819-EP2275420A1 Fenretinimide 33819-EP2298765A1 HMS3402G21 4-(hydroxyphenyl)retinamide LXS/4-HPR 65646-68-6 N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide AKOS024456572 NCGC00090752-02 SCHEMBL11704 ST-602 ZINC3871023 [ Show all ]
Inchi Key	AKJHMTWEGVYYSE-FXILSDISSA-N
Inchi ID	InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+
PubChem CID	5288209
ChEMBL	CHEMBL7301
IUPHAR	N/A
BindingDB	N/A
DrugBank	N/A
Structure SDF download
Lipinski's druglikeness	This ligand has a partition coefficient log P greater than 5.

Experimental Data

Parameter	Value	Reference	Database source
Potency	2909.1 nM	PubChem BioAssay data set	ChEMBL
Potency	7943.3 nM	PubChem BioAssay data set	ChEMBL

zhanglabzhanggroup.org | +65-6601-1241 | Computing 1, 13 Computing Drive, Singapore 117417